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Background:  Although the renin-angiotensin-aldosterone system (RAAS) is upregulated in diabetes (DM), whether direct renin inhibition offers 
benefit greater than other inhibitors of the RAAS in DM remains unknown.
Methods:  We investigated approaches to inhibiting the RAAS on left ventricular hypertrophy (LVH) regression and biomarkers in pts with and 
without DM in the Aliskiren in Left Ventricular Hypertrophy (ALLAY) trial. Hypertensive pts (n=465) with LVH and a BMI > 25 kg/m2 were randomized 
to aliskiren 300mg, losartan 100mg, or both daily for 36 weeks, and LVH regression was assessed by cardiac magnetic resonance imaging.
Results:  Pts with DM (n=111, 24%) were older (61±9 vs 58±11, p=0.03), had higher BMI (32.2±4.2 vs. 30.7 ± 4 kg/m2, p=0.004), higher systolic 
blood pressure (148±14 vs 145±14mmHg, p=0.03) and lower eGFR (79±16 vs 84±16mL/min, p=0.03) at baseline. Combination therapy was associated 
with greater LVH reduction than losartan alone in pts with DM (p=0.01), but not in pts without DM (p=0.91; p-interaction=0.059 -Figure), adjusting for 
degree of BP reduction. In 138 participants with biomarkers, plasma renin activity (PRA) was higher in those with DM (p=0.01) and aldosterone levels 
were similar at baseline, yet both were reduced to a greater extent in pts with DM compared with pts without DM (p-interaction < 0.03).
Conclusions:  Patients with DM and LVH may derive differential benefit from direct renin inhibition, which may be partially explained by greater 
reduction in PRA and aldosterone. 
